The combination of sorafenib and metformin inhibited the growth of HCC cells through the p62-Keap1-Nrf2/HO1 signaling pathway, as shown by the findings of the Nrf2 knockdown and p62 knockdown studies [42]. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.